Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challengeNature Medicine, 2014
- Enhancing poxvirus vectors vaccine immunogenicityHuman Vaccines & Immunotherapeutics, 2014
- Clinical development of Modified Vaccinia virus Ankara vaccinesVaccine, 2013
- Protective efficacy of Modified Vaccinia virus Ankara in preclinical studiesVaccine, 2013
- Poxvirus vectors as HIV/AIDS vaccines in humansHuman Vaccines & Immunotherapeutics, 2012
- Prime-boost vectored malaria vaccines: Progress and prospectsHuman Vaccines, 2010
- Synergistic DNA–MVA prime-boost vaccination regimes for malaria and tuberculosisVaccine, 2006
- Vaccinia Vectors as Candidate Vaccines: The Development of Modified Vaccinia Virus Ankara for Antigen DeliveryCurrent Drug Targets - Infectious Disorders, 2003
- Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein ExpressionBioTechniques, 1997
- Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal modelVaccine, 1996